You are here

  • Home
  • Archive
  • Volume 38, Issue 2
  • Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Article Text

Article menu
Download PDFPDF
Journal reviews
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
  1. Sam Hibbitts
  1. Senior Lecturer, HPV Research Group, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

https://doi.org/10.1136/jfprhc-2012-100337

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lehtinen M, Paavonen J, Wheeler CM, et al. Lancet Oncol 2012;13:89–99OpenUrlCrossRefPubMedWeb of Science

    Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

    Wheeler CM, Castellsagué X, Garland SM, et al. Lancet Oncol 2012;13:100–110OpenUrlCrossRefPubMedWeb of Science

    Persistent infection with high-risk (HR) human papillomavirus (HPV) is the underlying cause of cervical cancer. …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.